Compare Johnson & Johnson (JNJ) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Xylem, Inc. — how do they compare? Johnson & Johnson trades at $249.2 (market cap $598.96B), while Xylem, Inc. trades at $118.15 (market cap $28.67B). The key difference: Johnson & Johnson is far larger — about 20.9× Xylem, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | XYL | |
|---|---|---|
Market Cap | $598.96B | $28.67B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $152.95 |
52-Week Low | $164.36 | $106.34 |
Enterprise Value | $631.90B | $29.92B |
Dividend Yield | 2.15% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Xylem (XYL) trades at $120.64, down 1.74% over 24 hours, with a bullish technical signal from moving averages and strong support near $118. The company reported consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding the $1.08 estimate, and revenue growth from $5.5B in 2022 to $9.04B in 2025. Recent developments include a partnership with Gross-Wen Technologies and leadership appointments, reinforcing its position in water solutions.
Outlook remains positive with a consensus price target of $153, implying 27% upside, though risks include execution of growth initiatives and macroeconomic pressures on industrial demand. The stock offers a dividend yield supported by 16 consecutive years of increases, appealing for long-term investors seeking water infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
